GENinCode Plc
("GENinCode" or the "Company")
Result of AGM
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
A copy of the voting results can be found on the website later today here.
For more information visit www.genincode.com
Enquiries:
GENinCode Plc www.genincode.com or via Walbrook PR | Matthew Walls, CEO | Paul Foulger, CFO | Cavendish Capital Markets Limited Tel: +44 (0)20 7397 8900 | Giles Balleny / Trisyia Jamaludin (Corporate Finance) | Harriet Ward (Corporate Broking) Nigel Birks (Specialist Sales) | Walbrook PR Limited Anna Dunphy Tel: 020 7933 8780 or genincode@walbrookpr.com |
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGBDGDRCDGDGLB